Eli Lilly to acquire Dermira for $1.1 billion
16-01-2020
Fed Circ affirms Eli Lilly victories over cancer drugs
13-08-2019
16-06-2020
Jonathan Weiss / Shutterstock.com
The US Supreme Court has declined to review Eli Lilly’s patent infringement victory against Dr Reddy’s and Hospira.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Dr Reddy’s, Hospira, US Supreme Court, Alimta, cancer drug, generics, doctrine of equivalents